Back to Search Start Over

Eosinophilic myositis: an updated review.

Authors :
Selva-O'Callaghan A
Trallero-Araguás E
Grau JM
Source :
Autoimmunity reviews [Autoimmun Rev] 2014 Apr-May; Vol. 13 (4-5), pp. 375-8. Date of Electronic Publication: 2014 Jan 11.
Publication Year :
2014

Abstract

Eosinophilia-associated myopathies are clinically and pathologically heterogeneous conditions characterized by the presence of peripheral and/or muscle eosinophilia. There are at least three distinct subtypes: focal eosinophilic myositis, eosinophilic polymyositis, and eosinophilic perimyositis. Infiltrating eosinophils are not always identified in conventional muscle histologic examination, but the eosinophil major basic protein, whose extracellular diffusion is considered a hallmark of eosinophilic cytotoxicity, is usually detected by immunostaining in muscle biopsy. Whereas focal eosinophilic myositis seems to be a benign and isolated condition, and perimyositis is usually related with the inflammatory infiltrate due to fasciitis, eosinophilic polymyositis can be associated with muscular dystrophy or be a feature of multiorgan hypereosinophilic syndrome. Muscle biopsy remains the cornerstone for the diagnosis. Parasitic infections, connective tissue disorders, hematologic and non-hematologic malignancies, drugs, and toxic substances are the main etiologic agents of eosinophilia-associated myopathy. However, in some cases, no known etiologic factor is identified, and these are considered idiopathic. Glucocorticoids are the mainstay therapy in idiopathic forms. Imatinib and mepolizumab, a humanized anti-interleukin 5 monoclonal antibody, may be useful in patients with eosinophilic myositis as part of a hypereosinophilic syndrome.<br /> (Copyright © 2014 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1873-0183
Volume :
13
Issue :
4-5
Database :
MEDLINE
Journal :
Autoimmunity reviews
Publication Type :
Academic Journal
Accession number :
24424174
Full Text :
https://doi.org/10.1016/j.autrev.2014.01.018